Semax — Research Reference

Semax is a synthetic heptapeptide (7 amino acids) derived from the adrenocorticotropic hormone (ACTH) 4–7 sequence, with a C-terminal Pro-Gly-Pro extension added to improve stability and potency. It was developed in Russia and is approved as a pharmaceutical in Russia and Ukraine for clinical applications including stroke recovery, cognitive impairment, and optic nerve disease. In most other jurisdictions it is classified as a research compound.

Quick Reference

Overview

Semax was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences. It is structurally derived from the ACTH 4–10 fragment, which had previously been investigated for cognitive and neuroprotective effects, but with modifications designed to extend its biological activity without the adrenal stimulation associated with full-length ACTH.

Research has investigated Semax for its potential role in:

• Modulating brain-derived neurotrophic factor (BDNF) expression and its signalling receptor TrkB in hippocampal tissue
• Providing neuroprotection in models of ischaemia and traumatic brain injury
• Enhancing attention, memory, and cognitive performance in human research
• Reducing anxiety and stress responses via interaction with serotonin and dopamine pathways
• Improving recovery outcomes following stroke in Russian clinical trials

A key pharmacological characteristic is Semax’s reported ability to upregulate BDNF — a neurotrophic protein central to neuronal survival, synaptic plasticity, and long-term potentiation (LTP), which is the cellular basis of learning and memory.

The compound has a very short plasma half-life (minutes), but the reported persistence of cognitive effects over hours is proposed to result from receptor-level signalling cascades triggered during the brief exposure period.

Reported Protocols

The following information represents commonly reported research ranges drawn from anecdotal accounts and available published research. These are not medical recommendations.

Intranasal Protocol

Intranasal administration is the most commonly reported route in both anecdotal research accounts and clinical use in Russia. The nasal mucosa provides direct access to olfactory pathways, which researchers propose may facilitate CNS uptake beyond what systemic circulation alone would achieve.

Commonly reported doses range from 200 mcg to 600 mcg per day, administered in divided doses:

• Low range: 200–300 mcg total per day (100 mcg per nostril, once or twice daily)
• Mid range: 400–600 mcg total per day, divided across two to three administrations
• Timing: Anecdotal accounts frequently describe morning administration for cognitive effects and periodic use on an as-needed basis for high-demand cognitive periods
• Duration: Commonly reported research periods of 2 to 4 weeks, with some accounts describing longer cycles

Subcutaneous Protocol

Subcutaneous injection is reported to produce more reliable systemic absorption and is used in research contexts where precise dosing is required. Reported doses range from 100 mcg to 500 mcg per injection. Subcutaneous administration bypasses the variable absorption characteristic of the intranasal route.

Formulation Notes

Semax is commonly available in solution form at 0.1% (1 mg/ml) and 1% (10 mg/ml) concentrations in Russian pharmaceutical preparations. Researchers working with these preparations do not require reconstitution; lyophilized forms require reconstitution as described below.

Reported Effects

The following effects have been reported in clinical research and anecdotal accounts. This list reflects the research landscape, not confirmed clinical outcomes.

Cognitive Enhancement

Research has investigated Semax for its potential role in improving attention, processing speed, and working memory. Russian clinical data has reported improvements in cognitive performance in patients recovering from stroke and in individuals with mild cognitive impairment. Anecdotal research accounts describe improved focus, mental clarity, and motivation, particularly during cognitively demanding tasks.

BDNF Upregulation

Animal research has reported that Semax increases BDNF expression in hippocampal tissue — an effect proposed to underlie improvements in learning, memory consolidation, and neuroplasticity. BDNF upregulation is considered a primary mechanism of interest in Semax research.

Neuroprotection

Research has investigated Semax for its potential role in protecting neuronal tissue from ischaemic damage. Russian clinical data has reported reduced brain infarct size and improved neurological outcomes in stroke patients receiving Semax within the acute treatment window.

Anxiolytic Effects

Anecdotal reports and some preclinical data suggest anxiolytic (anxiety-reducing) activity. Some researchers describe a calming effect without sedation, which is attributed to proposed interactions with serotonin and dopamine systems.

Mood and Motivation

Anecdotal reports frequently describe improved mood, motivation, and reduced mental fatigue during Semax research cycles. The mechanism proposed in research accounts involves catecholamine modulation, including dopaminergic pathway activity.

Reported Side Effects

Reported side effects in research and anecdotal accounts include the following. This list does not constitute a comprehensive safety profile and should not be interpreted as predictive of individual outcomes.

Note on psychological effects: As a centrally acting compound, Semax may interact with mood-regulating systems. Some anecdotal researchers report a period of increased irritability or emotional blunting following extended use. Individual responses to central nervous system peptides vary considerably.

The compound has not undergone comprehensive safety evaluation in research chemical contexts outside of Russian clinical trials.

Storage & Handling

Lyophilized Powder (Unreconstituted)

• Room temperature: Reported stable for up to 3 months when kept away from light and moisture
• Refrigerator (2–8°C): Preferred for extended storage; protect from light
• Freezer: Acceptable for long-term storage; avoid repeated freeze-thaw cycles
• Light sensitivity: Protect from light; store in an opaque container

Reconstituted or Pharmaceutical Solution

• Refrigerator (2–8°C): Use within the stated expiry period; typically 2–3 years unopened
• Once opened, most preparations are designed for use within 30 days when refrigerated
• Do not freeze a reconstituted or pharmaceutical solution
• Discard if the solution becomes cloudy, discoloured, or shows particulate matter

Reconstitution

For lyophilized forms: Add sterile saline or bacteriostatic water slowly along the inside wall of the vial. Swirl gently — do not shake. See the Reconstitution Guide for step-by-step instructions.

Frequently Asked Questions

What is the difference between Semax and Selank? Semax and Selank are both Russian-developed nootropic peptides with different primary mechanisms. Semax is derived from ACTH and is more focused on cognitive enhancement, BDNF upregulation, and neuroprotection. Selank is derived from tuftsin and is primarily reported for anxiolytic effects and immune modulation, with cognitive effects as secondary. Many researchers describe the compounds as complementary rather than interchangeable.

Why is the half-life so short if the effects last hours? The very short plasma half-life (minutes) reflects how quickly Semax is cleared from the blood. However, once the peptide has bound to and activated its targets — triggering downstream signalling cascades including BDNF expression — these effects persist independently of the continued presence of the peptide. This is a common feature of receptor-mediated signalling biology.

Is Semax legal to purchase? The regulatory status of Semax varies by country. It is approved as a pharmaceutical in Russia and Ukraine. In most Western countries (USA, EU, UK, Australia), it exists in a grey area — not approved as a medicine, but often not explicitly scheduled as a controlled substance. Researchers should verify the regulatory status in their jurisdiction.

Can Semax be used daily? Anecdotal research accounts describe both daily use and periodic use. Some researchers describe tolerance development with continuous daily use and prefer cycle protocols of 2–4 weeks with breaks. Others report sustained benefit with ongoing daily intranasal administration. The long-term effects of continuous use have not been formally studied.

Related Pages

Goals: Cognitive Support · Neuroprotection

Class: Nootropic Peptides

Comparisons: Semax vs Selank

References & Further Reading

• Dolotov OV, et al. (2006). Semax, an analog of ACTH (4-7) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. PubMed →
• Manchenko DM, et al. (2010). Semax, a synthetic analogue of ACTH 4-10, attenuates the effects of withdrawal from chronic morphine treatment. Bulletin of Experimental Biology and Medicine, 148(6), 873–876. PubMed →
• Grigorjeva ME, Lyapina LA. (2017). The regulatory influence of semax peptide on the system of fibrinolysis and blood coagulation under conditions of experimental ischemia. Bulletin of Experimental Biology and Medicine, 163(1), 53–56. PubMed →